ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

• Published in: Annals of neurology Vol. 45; no. 6; pp. 736 - 741
• Main Authors: Rascol, O., Blin, O., Thalamas, C., Descombes, S., Soubrouillard, C., Azulay, P., Fabre, N., Viallet, F., Lafnitzegger, K., Wright, S., Carter, J. H., Nutt, J. G.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 01.06.1999; Willey-Liss
• Subjects: Aged; Anticonvulsants. Antiepileptics. Antiparkinson agents; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Double-Blind Method; Female; Humans; Male; Medical sciences; Middle Aged; Neurology; Neuropharmacology; Parkinson Disease - drug therapy; Pharmacology. Drug treatments; Prodrugs - adverse effects; Prodrugs - pharmacology; Prodrugs - therapeutic use; Pyridines - adverse effects; Pyridines - pharmacology; Pyridines - therapeutic use; Tetrahydronaphthalenes - adverse effects; Tetrahydronaphthalenes - pharmacology; Tetrahydronaphthalenes - therapeutic use; Human; Nervous system diseases; Agonist; D1 Dopamine receptor; Parkinson disease; Prodrug; Antiparkinson agent; Cerebral disorder; Previous study; Chemotherapy; Treatment; Central nervous system disease; Degenerative disease; Extrapyramidal syndrome
• ISSN: 0364-5134; 1531-8249
• DOI: 10.1002/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F

Studies in animal models show a selective D1 receptor agonist with full functional efficacy compared with dopamine to have antiparkinsonian efficacy of similar magnitude to levodopa, without the same propensity for inducing dyskinesia. To date, no such agent has been tested in humans. ABT‐431 is the prodrug of A‐86929, a full, selective D1 receptor agonist. Subjects (n = 14) with levodopa‐responsive Parkinson's disease received five doses of ABT‐431 (5, 10, 20, 30, and 40 mg) and one of placebo after a 12‐hour levodopa holiday. Response was assessed by using the Unified Parkinson's Disease Rating Scale motor subsection. Dyskinesia was separately graded. ABT‐431 showed efficacy significantly superior to placebo at doses of 10 mg and more, and of similar magnitude to that seen with levodopa. Dyskinesia was reduced in several patients after receiving ABT‐431. There were no serious adverse events, the most common minor events being nausea and emesis, dizziness, and hypotension. Assuming that ABT‐431 is not transformed in humans into an unknown active D2 metabolite, and remains selective for D1 receptors, it is the first dopamine D1 receptor agonist to demonstrate a full antiparkinsonian effect in patients with Parkinson's disease. These preliminary findings also suggest that it may exhibit a reduced tendency to provoke dyskinesia. The emergence of a well‐tolerated D1 agonist should allow for the development of a better understanding of the relation between motor efficacy and dyskinesia in Parkinson's disease. Ann Neurol 1999;45:736–741